Healthcare Policy Implications of Heterogeneity of Treatment Effects

American Journal of Medicine

Volumn 120, Issue 4 SUPPL., 2007, Pages

  McLaughlin, Michael J ^a  

^a Peloton Advantage   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; EVIDENCE BASED MEDICINE; HEALTH CARE POLICY; HEALTH CARE QUALITY; HUMAN; MEDICAL PRACTICE; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; FEMALE; GENETICS, POPULATION; HEALTH POLICY; HUMANS; MALE; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PHYSICIAN'S PRACTICE PATTERNS; POLICY MAKING; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 33947676345     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2007.02.006     Document Type: Article

References (8)

1. Kravitz R.L., Duan N., and Braslow J. Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Q 82 (2004) 661-687
2. Goldstein D.B., Need A.C., Singh R., and Sisodiya S.M. Potential genetic causes of heterogeneity of treatment effects. Am J Med 120 (2007) S21-S25
3. Greenfield S., Kravitz R., Duan N., and Kaplan S.H. Heterogeneity of treatment effects: implications for guidelines, payment, and quality assessment. Am J Med 120 (2007) S3-S9
4. Materson B.J. Variability in response to antihypertensive drugs. Am J Med 120 (2007) S10-S20
5. Stroup T.S. Heterogeneity of treatment effects in schizophrenia. Am J Med 120 (2007) S26-S31
6. Schinkel J., Spaan W.J., and Kroes A.C. Meta-analysis of mutations in the NS5A gene and hepatitis C virus resistance to interferon therapy: uniting discordant conclusions. Antivir Ther 9 (2004) 275-286
7. Meadows M. FDA approves heart drug for black patients. FDA Consum 39 (2005) 8-9
8. Chang L., and Heitkemper M.M. Gender differences in irritable bowel syndrome. Gastroenterology 123 (2002) 1686-1701